SG Americas Securities LLC Acquires Shares of 9,745 Entrada Therapeutics, Inc. (NASDAQ:TRDA)

SG Americas Securities LLC bought a new position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 9,745 shares of the company’s stock, valued at approximately $156,000.

Other large investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its position in Entrada Therapeutics by 427.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after purchasing an additional 11,965 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after buying an additional 13,742 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Entrada Therapeutics during the first quarter worth $79,000. Bank of New York Mellon Corp lifted its stake in shares of Entrada Therapeutics by 13.4% during the second quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock valued at $1,787,000 after acquiring an additional 14,838 shares during the period. Finally, Rhumbline Advisers boosted its holdings in Entrada Therapeutics by 25.3% in the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after acquiring an additional 7,452 shares during the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Entrada Therapeutics Stock Down 0.8 %

NASDAQ:TRDA opened at $16.84 on Friday. Entrada Therapeutics, Inc. has a 12-month low of $10.75 and a 12-month high of $18.17. The stock’s fifty day simple moving average is $16.13 and its 200-day simple moving average is $15.28. The firm has a market capitalization of $626.45 million, a P/E ratio of 5.69 and a beta of -0.25.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.90. The firm had revenue of $94.69 million for the quarter, compared to analyst estimates of $55.00 million. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%. As a group, equities research analysts expect that Entrada Therapeutics, Inc. will post 0.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on TRDA. Oppenheimer reissued an “outperform” rating and set a $25.00 price objective on shares of Entrada Therapeutics in a report on Monday, August 26th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 14th.

Insider Buying and Selling

In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 2,642 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $15.09, for a total value of $39,867.78. Following the completion of the sale, the insider now owns 183,816 shares of the company’s stock, valued at approximately $2,773,783.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78. Following the transaction, the insider now directly owns 183,816 shares in the company, valued at approximately $2,773,783.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kory James Wentworth sold 3,195 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $14.97, for a total value of $47,829.15. Following the completion of the transaction, the chief financial officer now directly owns 76,486 shares of the company’s stock, valued at approximately $1,144,995.42. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,187 shares of company stock valued at $155,947 in the last 90 days. 7.59% of the stock is owned by insiders.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.